FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q2 2026

Top Holdings89 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
SPYSPY
PUT

STATE STR SPDR S&P 500 ETF T

6M$4.5B20.7%
New

REVOLUTION MEDICINES INC

13.6M$2.5B11.7%$35.04+493.29%
22 qtrssince 2021-Q1
Decreased
0

ELECTRONIC ARTS INC

7.9M$1.6B7.5%$203.43+3.08%
3 qtrssince 2025-Q4
Increased
66

BRIDGEBIO PHARMA INC

10.7M$800.1M3.7%$43.29+76.93%
8 qtrssince 2024-Q3
Increased
67

PROTAGONIST THERAPEUTICS INC

6.3M$778.2M3.6%$21.66+566.37%
31 qtrssince 2018-Q4
Unchanged
0

EXELIXIS INC

13.5M$732.8M3.4%$23.79+128.87%
31 qtrssince 2018-Q4
Increased
60

LIQUIDIA CORPORATION

8.4M$666.9M3.1%$18.28+270.24%
10 qtrssince 2024-Q1
Decreased
0

AMAZON COM INC

2.6M$627.5M2.9%$225.22+18.30%
5 qtrssince 2025-Q2
Decreased
0

LANTHEUS HLDGS INC

5.6M$619.4M2.9%$78.29+28.71%
14 qtrssince 2023-Q1
Unchanged
0

NATERA INC

2.2M$602.2M2.8%$74.46+338.19%
21 qtrssince 2021-Q2
Decreased
0

UNITEDHEALTH GROUP INC

1.3M$528.1M2.4%$422.06-6.90%
14 qtrssince 2023-Q1
Decreased
0

THERMO FISHER SCIENTIFIC INC

1M$526M2.4%$473.68+31.35%
27 qtrssince 2019-Q4
Increased
63

ROIVANT SCIENCES LTD

14.3M$506.4M2.3%$30.25+14.75%
13 qtrssince 2023-Q2
Increased
74

AON PLC

1.4M$458.6M2.1%$329.96+7.71%
10 qtrssince 2024-Q1
Decreased
0

BOSTON SCIENTIFIC CORP

10.5M$449M2.1%$64.74-27.65%
24 qtrssince 2020-Q3
Increased
71

BROADCOM INC

1.2M$435.1M2.0%$326.98+12.79%
3 qtrssince 2025-Q4
Decreased
0

MICROSOFT CORP

1.1M$415.1M1.9%$340.17+50.96%
31 qtrssince 2018-Q4
Decreased
0

TANGO THERAPEUTICS INC

12.3M$383.8M1.8%$12.04+93.90%
7 qtrssince 2024-Q4
Increased
63

KKR & CO INC

4.1M$378M1.7%
Decreased
0

SYNOPSYS INC

829,600$370.1M1.7%$465.64-4.95%
3 qtrssince 2025-Q4
Decreased
0
$21.7B
AUM
89
Positions
Q2 2026
Filing
1.5/5
HI score
Quarterly 13F Value Change
-2%Q1'25$18.5B+18%Q2'25$21.9B-19%Q3'25$17.7B+9%Q4'25$19.2B-12%Q1'26$16.9B+1%Q2'26$17.1B
Activity profile
$ moved · Q2'26
New33%Increased15%Decreased22%Exited31%
Composition
Equity vs derivatives
Equity79%Puts21%Calls0%
Holding period
Avg 2.4 years
<1Q22%1-4Q24%1-2Y10%2Y+44%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $21.7B across 89 positions as of Q2 2026. Top holdings: SPY (20.7%), RVMD (11.7%), EA (7.5%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1.5/5.0.

Q2 2026 Summary

Active quarter - 20 new positions, 104 exits, 29 increased. Top move: ROIV (INCREASED, conviction 74). Portfolio: $21.7B across 89 positions.

Top holdings by portfolio weight

Total AUM$17B
RVMD11.71%
EA7.49%
BBIO3.69%
PTGX3.59%
EXEL3.38%
LQDA3.08%
AMZN2.90%
LNTH2.86%
NTRA2.78%
UNH2.44%
Other2.43%

Portfolio allocation by GICS sector

Sectors10
Healthcare69.97%
Communication Services10.84%
Technology7.35%
Financial Services5.12%
Consumer Cyclical3.79%
Industrials2.66%
Basic Materials0.26%
Energy0.01%
Real Estate0.00%
Consumer Defensive0.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Communication Services
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(1.5 / 5.0)
Holdings P&L60
Conviction45
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used